Recruiting Prurigo Nodularis Studies in Scottsdale
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis....
A Study of Barzolvolimab in Patients With Prurigo Nodularis
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis....
About Prurigo Nodularis Clinical Trials in Scottsdale
Prurigo nodularis is a chronic skin condition characterized by intensely itchy, hard lumps on the skin that develop from repeated scratching. It significantly impacts quality of life and sleep. Treatment includes topical therapies, phototherapy, and newer targeted biologics.
There are currently 2 prurigo nodularis clinical trials recruiting participants in Scottsdale, AZ. These studies are seeking a combined 450 participants. Research is being sponsored by Incyte Corporation, Celldex Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.
Prurigo Nodularis Clinical Trials in Scottsdale — FAQ
Are there prurigo nodularis clinical trials in Scottsdale?
Yes, there are 2 prurigo nodularis clinical trials currently recruiting in Scottsdale, AZ. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Scottsdale?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Scottsdale research site will contact you about next steps.
Are clinical trials in Scottsdale free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Scottsdale studies also compensate for your time and travel.
What prurigo nodularis treatments are being tested?
The 2 active trials in Scottsdale are testing new therapies including novel drugs, biologics, and treatment approaches for prurigo nodularis.
Data updated March 2, 2026 from ClinicalTrials.gov